---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-028716"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2026-07-16T20:35:25+00:00"
generated_at: "2026-07-16T20:36:43.968004+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Gyre Therapeutics appoints three new directors to its board, effective August 1, 2026

## Summary
- Yue Xiong (CSO) appointed as Class I director; no additional compensation for board service.
- Maxwell Kirkby appointed as Class II director and to Compensation Committee; receives 40k stock options vesting over 3 years.
- Claire Weston appointed as Class III director and to Audit Committee; receives same option grant.
- Appointments expand board expertise in scientific, clinical development, and cross-border operations.
- Effective date August 1, 2026; terms expire at 2027, 2028, and 2029 annual meetings respectively.

## SEC filing metadata
- accession: 0001140361-26-028716
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2026-07-16T20:35:25+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036126028716/0001140361-26-028716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036126028716/ef20078088_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-028716
- JSON: https://secwatch.observer/filing/0001140361-26-028716.json
- Plain text: https://secwatch.observer/filing/0001140361-26-028716.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.